Phase II Study of Olaparib in Combination With Pembrolizumab in Patients With Advanced Melanoma With Homologous Recombination (HR) Pathway Gene Mutation
Latest Information Update: 08 Dec 2022
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 30 Apr 2021 Status changed from not yet recruiting to recruiting.
- 12 Jan 2021 Planned initiation date changed from 1 Dec 2020 to 1 Feb 2021.
- 23 Nov 2020 New trial record